Processa Pharmaceuticals, Inc. (PCSA) News
Follow Processa Pharmaceuticals, Inc. (PCSA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
PCSA advances VT-7208 into phase II trials
PCSA said a recent merger and a $200 million PIPE position it to advance VT-7208, a next-generation BTK inhibitor, into three parallel phase II trials targeting food allergy, CSU and relapsing MS.
MNA | Sep 10, 2026, 03:11 PM UTC
H
PCSA: Merger and funding enable rapid phase II development of VT-7208, a differentiated BTK inhibitor
A recent merger and $200M PIPE have positioned the company to advance VT-7208, a next-gen BTK inhibitor, into three phase II trials targeting food allergy, CSU, and relapsing MS. Early data show strong safety, CNS penetr
MNA | Sep 10, 2026, 02:59 PM UTC
L
Processa Pharmaceuticals to participate in upcoming investor conferences
Processa Pharmaceuticals said it will participate in two upcoming investor conferences.
EQUITY | Sep 01, 2026, 11:08 AM UTC
L
PCSA - Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
PCSA - Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
EQUITY | Sep 01, 2026, 11:01 AM UTC
H
Crude Oil Surges 7%; General Dynamics Posts Upbeat Earnings
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 800 points on Wednesday. The Dow traded down 1.58% to 51,915.42 while the NASDAQ declined 1.19% to 24,580.72. The S&P 500 also f
EARNINGS | Jul 29, 2026, 04:02 PM UTC
H
Dow Tumbles 400 Points; Procter & Gamble Shares Fall After Q4 Results
U.S. stocks traded mostly lower this morning, with the Dow Jones index falling more than 400 points on Wednesday. Following the market opening Wednesday, the Dow traded down 0.78% to 52,334.00 while the NASDAQ declined 0
EARNINGS | Jul 29, 2026, 01:46 PM UTC
H
PCSA Acquires Vidya Therapeutics
PCSA buys Vidya Therapeutics for BTK inhibitor
MNA | Jul 29, 2026, 11:30 AM UTC